Acorda Therapeutics (STU:CDG) EV-to-Revenue : 1.62 (As of May. 25, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Acorda Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Acorda Therapeutics's enterprise value is €173.3 Mil. Acorda Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €106.9 Mil. Therefore, Acorda Therapeutics's EV-to-Revenue for today is 1.62.

The historical rank and industry rank for Acorda Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:CDG' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7 Med: 1.72 Max: 4.65
Current: 1.62

During the past 13 years, the highest EV-to-Revenue of Acorda Therapeutics was 4.65. The lowest was 0.70. And the median was 1.72.

STU:CDG's EV-to-Revenue is ranked better than
65.72% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs STU:CDG: 1.62

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Acorda Therapeutics's stock price is €9.36. Acorda Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €86.04. Therefore, Acorda Therapeutics's PS Ratio for today is 0.11.

Acorda Therapeutics EV-to-Revenue Historical Data

The historical data trend for Acorda Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics EV-to-Revenue Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1.15

1.49

1.37

1.30

1.53

Acorda Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1.36	1.47	1.55	1.53	1.75

Competitive Comparison of Acorda Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's EV-to-Revenue falls into.

Acorda Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Acorda Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	173.345	/	106.857
	=	1.62

Acorda Therapeutics's current Enterprise Value is €173.3 Mil.
Acorda Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €106.9 Mil.

Acorda Therapeutics (STU:CDG) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Acorda Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	9.36	/	86.036
	=	0.11

Acorda Therapeutics's share price for today is €9.36.
Acorda Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €86.04.

Acorda Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (STU:CDG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (STU:CDG) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ACOR:USA

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (STU:CDG) Headlines

No Headlines